High-Purity TRAIL Soluble Mouse Recombinant for Efficient Cancer Research
ProcurenetShort description
The TRAIL Soluble Mouse Recombinant is a highly purified, >95% SDS-PAGE, His-tagged apoptosis-inducing ligand. It is produced in E. coli, making it robust and versatile for various applications. Key features include:
n
- n
- Recombinant expression ensures a high degree of reproducibility and supply stability.
- His-tagged for efficient detection and purification.
- Has applications in multiple research areas, including transmembrane protein study, apoptosis, and cell death.
- Varieties include Apo-2L, CD253, JAG2, TRAIL, making this product adaptable to a range of research needs.
n
n
n
n
-
Procurenet Team Tshim Sha Tsui
Hong Kong
3 years
Description
TRAIL Soluble Mouse Recombinant
Introducing the TRAIL Soluble Mouse Recombinant – a versatile research tool delivering greater than 95% purity confirmed by SDS-PAGE. This high-quality biochemical tool is expressed in E. coli, ensuring exceptional yield and maintainability.
Essentially a soluble version of the mouse recombinant TNF-related apoptosis-inducing ligand (TRAIL), this protein owes its extraordinary purity to the His tag incorporated during expression. This His tag also facilitates simple and practical purification processes.
Known by several names including Apo-2L, CD253, JAG2, and TNFSF10. The TRAIL protein is a vital component of the TNF superfamily and is given significance due to its role as a type II transmembrane protein. Weighing approximately 34kDa, TRAIL’s role in cellular processes and potential applications in biomedical research and therapy are far-reaching.
Key Features of TRAIL Soluble Mouse Recombinant
- Representing the soluble form of the mouse recombinant TRAIL
- Expression realized in E. coli for optimal output
- Incorporation of His tag enables straightforward purification
- Confirmed >95% purity through SDS-PAGE analysis
- @34kDa Type II transmembrane protein
- Crucial member of the TNF superfamily
- Shows selective apoptosis induction in cancer cells
- Potential powerful resource for cancer treatment
Researchers have found TRAIL’s selective apoptosis-inducing properties of utmost interest, making it a strong contender for cancer treatment. Initial research has demonstrated immensely encouraging results, showing the protein’s ability to focus solely on cancer cells while sparing all normal cells.
As TRAIL binds with death receptors like DR4 and DR5, that are selectively placed on the cancer cell surface, it triggers a set of internal cellular reactions that eventually lead to apoptosis. The recombinant TRAIL can aid researchers in understanding the functionality of TRAIL, its interaction with other proteins, and its potential therapeutic application.
